Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinicalâstage biopharmaceutical c...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a c...
The mission of Mighty Well is to help patients and their caregivers turn sickness ...
The mission of Mighty Well is to help patients ...
Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...
Tonix is a clinical-stage biopharmaceutical com...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...
Biocept, Inc. is a molecular diagnostics compan...
Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and develop...
Aptinyx Inc. is a clinical-stage biopharmaceuti...
Join the National Investor Network and get the latest information with your interests in mind.